SandboxAQ Releases Synthetic Data to Accelerate Drug Discovery
SandboxAQ, an AI startup backed by NVIDIA, has released a dataset of 5.2 million synthetic three-dimensional molecules to accelerate drug discovery. The data, generated using NVIDIA's chips, aims to predict drug-protein binding, a crucial step in developing new medical treatments. This synthetic data, validated by real-world experiments, will be used to train AI models that can rapidly predict whether a small-molecule pharmaceutical will bind to its target protein, potentially saving significant time compared to traditional lab experiments.
The approach combines traditional scientific computing with AI advancements, addressing the challenge of calculating vast combinations of small pharmaceutical molecules. SandboxAQ's synthetic data, publicly available, allows scientists to train AI models to predict drug-protein interactions accurately and efficiently. The company plans to monetize its AI models developed with this data, offering a virtual alternative to lab experiments.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Apodex Offers Free AI Drug Research Services
Danaher and NVIDIA Bring AI Into Laboratory Instruments
SAS and NC State Launch AI Research Partnership
Novo Nordisk Partners With Anthropic on Drug Research
Perplexity Open Sources SPACE Agent Sandbox
Daily AI Brief: the AI news that matters, in your inbox.